Centessa gets FDA IND clearance for Phase 1/2a trial of LB101 LockBody candidate for solid tumors

Centessa Pharmaceuticals plc

FDA cleared IND for LB101, a PD-L1xCD47 bispecific LockBody antibody, for solid tumors.
First LockBody candidate to enter clinic; designed to activate CD47 in tumor microenvironment avoiding systemic toxicity.
CEO Saurabh Saha calls it an important milestone; company plans to advance multiple LockBody candidates.
Phase 1/2a first-in-human trial initiation expected as soon as possible.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.